mipomersen inn trade name kynamro drug used treat homozygous familial hypercholesterolemia administered subcutaneous injection serious risk liver damage drug prescribed context risk management plan kynamro used treat homozygous familial hypercholesterolemia administered freely prescribed instead every person put mipomersen enrolled risk evaluation mitigation strategies rems program approved mipomersen pregnancy category b women pregnant intending become pregnant use drug needed unknown secreted human breast milk found secreted breast milk drug contraindicated people moderate severe liver impairment active liver diseases unexplained high levels transaminase liver drug black box warning risk liver damage specifically cause elevations levels transaminases causes fatty liver clinical trials subjects taking mipomersen stopped using drug due adverse effects common adverse effects leading discontinuation injection site reactions increases transaminases flulike symptoms fever chills abdominal pain nausea vomiting abnormal liver adverse effects include heart problems including angina palpitations edema pain legs arms headache insomnia drugs known causing liver problems might add mipomersens risk liver damage pharmacokinetic interactions mipomersen binds messenger rna coding apolipoprotein protein main component lowdensity lipoprotein ldl lowdensity lipoprotein vldl consequence rna degraded enzyme ribonuclease h subcutaneous injection mipomersen reaches highest blood levels hours accumulates livercitation needed convenient since apolipoprotein b predominantly acts protein binding molecule slowly broken endonucleases subsequently exonucleases hours less degradation products found urine overall halflife compound secondgeneration antisense oligonucleotide nucleotides linked phosphorothioate linkages rather phosphodiester linkages rna dna sugar parts deoxyribose middle part molecule omethoxyethylmodified ribose two ends modifications make drug resistant degradation nucleases allowing administered weekly complete sequence portrayed drug discovered developed phase ionis pharmaceuticals subsequently licensed genzyme corporation auction bid ionis earned upfront payment million payments million milestones mipomersen rejected european medicines agency due concerns liver cardiovascular adverse january united states food drug administration approved mipomersen treatment homozygous familial httpsenwikipediaorgwikimipomersen